Business Context and Reporting Period
This Form 8-K filing by Rocket Pharmaceuticals, Inc. (RCKT) reports on events occurring on September 11, 2025. The filing details the departure of Dr. Kinnari Patel, who is leaving the company to become a venture partner at RTW Investments LP.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the financial terms of a specific executive separation and subsequent consulting arrangement.
| Item | Value |
|---|---|
| Severance Lump Sum | $482,040 |
| Healthcare Allowance (COBRA) | $30,045 |
| Consulting Retainer Fee | $582,156 |
| Total Agreed Compensation | $1,094,241 |
Material Changes
The primary material change is the execution of a Separation and Release Agreement and a Consulting Agreement with Dr. Patel. Key terms include:
- Separation Date: December 31, 2025.
- Benefits: Salary and benefits continue through the Separation Date, plus payment for accrued unused paid time off.
- Severance Condition: The $482,040 lump sum is contingent upon Dr. Patel delivering an executed release of claims within seven days of the Separation Date.
- Consulting Role: Dr. Patel will serve as a consultant from the expiration of the release revocation period through December 31, 2026.
- Equity: Dr. Patel retains all restricted stock units and options granted under company plans through the Consulting Period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or general risk factors beyond the specific terms of the executive agreements. The agreements include standard restrictive covenants and a general release of claims in favor of the Company and its affiliates.
Investor Verification Checklist
- Verify the exact start date of the Consulting Period, which depends on the expiration of the revocation period for the Release of Claims.
- Confirm the total cash outflow impact ($1,094,241) against the company's current cash position in the most recent 10-Q or 10-K.
- Review the full text of Exhibits 10.1 and 10.2 for specific restrictive covenants and termination clauses not summarized in the 8-K.
- Assess the strategic impact of Dr. Patel's departure on the company's clinical development pipeline or operational leadership.